FDA Accepts TransCon® CNP NDA for Priority Review
Provided By GlobeNewswire
Last update: Jun 2, 2025
– Once-weekly TransCon CNP demonstrated significantly higher annualized growth velocity, the primary endpoint, compared to placebo
– Multiple benefits beyond linear growth were observed compared to placebo, with a safety and tolerability profile similar to placebo
Read more at globenewswire.com
